Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Buy" by Analysts

Key Points

• Kymera Therapeutics (NASDAQ:KYMR) has received a consensus recommendation of "Buy" from twenty research firms, with an average target price of $59.11 for the next year.
• Significant insider trading includes Director Bros. Advisors Lp Baker purchasing 655,500 shares at $44.00 per share, marking a 12% increase in his ownership.
• In recent earnings, Kymera Therapeutics reported a quarterly revenue of $22.1 million, significantly exceeding analyst expectations and showing a 114.6% increase compared to the same quarter last year.

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus recommendation of "Buy" by the twenty research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $59.1111.

Several equities analysts have commented on the stock. Oppenheimer reissued an "outperform" rating and issued a $53.00 target price (down from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target on the stock in a report on Wednesday, July 30th. Wells Fargo & Company decreased their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a report on Thursday, June 26th. BTIG Research reaffirmed a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 26th. Finally, Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $55.00 price target on the stock.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Bros. Advisors Lp Baker purchased 655,500 shares of the company's stock in a transaction dated Monday, June 30th. The shares were purchased at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the transaction, the director owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 over the last quarter. Insiders own 16.01% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in shares of Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the period. State of Wyoming acquired a new position in shares of Kymera Therapeutics in the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics in the 4th quarter worth approximately $55,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics in the 1st quarter worth approximately $68,000.

Kymera Therapeutics Stock Down 0.6%

KYMR stock opened at $40.62 on Monday. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27. The firm has a market cap of $2.65 billion, a P/E ratio of -13.10 and a beta of 2.18. The company's 50-day moving average price is $45.11 and its two-hundred day moving average price is $36.47.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same period last year, the firm earned ($0.69) EPS. The business's quarterly revenue was up 114.6% compared to the same quarter last year. Equities analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.